Rheumatic diseases in HIV-infected patients in the post-antiretroviral therapy era: a tertiary care center experience
AffiliationUniv Arizona, Coll Med
MetadataShow full item record
PublisherSPRINGER LONDON LTD
CitationParperis, K., Abdulqader, Y., Myers, R., Bhattarai, B., & Al-Ani, M. (2018). Rheumatic diseases in HIV-infected patients in the post-antiretroviral therapy era: a tertiary care center experience. Clinical rheumatology, 1-6.
Rights© International League of Associations for Rheumatology (ILAR) 2018
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractThe aim of the study was to calculate the proportion of rheumatic diseases in HIV patients who were receiving ART and to identify association of the HIV medications with the development of rheumatologic diseases. We conducted a retrospective chart review during the period of 2010 to 2016. We identified 2996 patients as having chronic HIV infection and on ART, and we collected data regarding patient's demographic characteristics, comorbidities, CD 4 count, HIV viral load, and ART. One hundred thirteen out of 2996 HIV patients (3.8%) were found to have a rheumatic condition (mean age of 48.6 years, 83% male). The most frequent musculoskeletal condition was avascular necrosis (AVN) in 39 (1.3%), and the most frequent autoimmune condition was psoriasis in 28 patients (1%). Compared with the 200 HIV patients without any diagnosis of rheumatic disease were the older patients with rheumatic conditions (mean age of 48.9 vs. 42.7 years; p < 0.01), and had a longer duration of HIV infection (mean duration of 15.5 vs. 10.3 years; p < 0.01). The odds of rheumatic conditions were 1.7 times higher in males (relative to females). Those who received integrase inhibitors were more likely (63.3%) to develop rheumatologic manifestations relative to those who never received integrase inhibitors (21.6%; p < 0.01). The proportion of rheumatic diseases in HIV patients appears to be comparable to the prevalence in the US population. Older age, longer duration of HIV infection, and the use of ART regimens containing integrase inhibitors, appear to increase the risk of developing a rheumatic condition.
Note12 month embargo; first online: 04 April 2018
VersionFinal accepted manuscript
- Rheumatic manifestations in HIV-1 infected in-patients and literature review.
- Authors: Yao Q, Frank M, Glynn M, Altman RD
- Issue date: 2008 Sep-Oct
- Human immunodeficiency virus-associated rheumatic disorders in the HAART era.
- Authors: Marquez J, Restrepo CS, Candia L, Berman A, Espinoza LR
- Issue date: 2004 Apr
- Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy.
- Authors: Yang JJ, Tsai MS, Sun HY, Hsieh SM, Chen MY, Sheng WH, Chang SC
- Issue date: 2015 Apr
- Assessment and management of musculoskeletal disorders among patients living with HIV.
- Authors: Walker-Bone K, Doherty E, Sanyal K, Churchill D
- Issue date: 2017 Oct 1
- Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
- Authors: Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J
- Issue date: 2013 Nov